CVS Health (CVS) touched a 52-week high of $92.77 on Monday, with a year-to-date gain of over 16%, outpacing the S&P 500’s 8% increase over the same period. The company’s strong first-quarter earnings report released earlier boosted investor confidence that its business is getting back on track.
In recent years, CVS Health faced certain operational pressures due to rising costs, but the company’s situation has since improved significantly. Although the stock has doubled since the beginning of 2026, the market still sees potential for further upside.
On May 6, CVS Health announced its first-quarter 2026 results, with revenue rising more than 6% to $100.4 billion. Net income approached $3 billion, a year-over-year increase of 66%. Another key metric—the medical benefit ratio (MBR)—declined to 84.6% from 87.3% in the same period last year. This metric reflects the proportion of medical claims paid by the company relative to the premiums collected. Previously, rising healthcare utilization kept the MBR elevated, putting pressure on profits. The recent decline suggests that cost trends are becoming more predictable.
Despite the stock hitting a new high, CVS Health’s forward price-to-earnings ratio (based on analyst estimates) is just 13 times, while the average forward P/E for S&P 500 constituents is 22 times. Given the company’s stability and potential growth upside, the current valuation remains reasonable.
Over the past five years, CVS Health’s stock has gained only about 9% cumulatively, reflecting the operational difficulties it previously faced. Beyond share price appreciation, the company also offers a 2.9% dividend yield, providing investors with steady recurring income.
CVS Health operates three core business segments: healthcare benefits, health services, and pharmacy & consumer health. In the first quarter, all three segments achieved revenue growth of at least 9%. Within these, the medical benefit ratio of its Aetna unit has fallen to approximately 91% after spiking in prior years, indicating progress in pricing efficiency and cost management in its Medicare Advantage plans.
The company operates about 1,000 walk-in clinics and primary care centers (including MinuteClinics and approximately 230 Oak Street Health centers designed for seniors). These facilities have effectively improved medication adherence among its insurance members and reduced hospitalization rates. Such internal synergies are difficult for pure-play retailers or insurers to replicate.
CVS Health froze its dividend at $0.50 per share between 2017 and 2021 to repay debt incurred from the Aetna acquisition (a $69 billion transaction). The company has never cut its dividend and has increased it by 33% since 2022. At the current share price, the dividend yield stands at a healthy 3.46%, with a payout ratio of 43.5%, indicating the company has capacity to continue raising its dividend.
The company continues to generate robust cash flow, with $10.6 billion in operating cash flow in 2025, and expects at least $9 billion in 2026.
The market had previously expected the Centers for Medicare & Medicaid Services (CMS) to increase Medicare payment rates by only 0.9%, but the actual increase was 2.48%. This is expected to boost the profitability of the Aetna unit this year.
Company management expects full-year revenue of at least $400 billion this year, roughly flat compared with 2025, and projects that adjusted earnings per share will grow at a compound annual rate of around 15% over the next three years.
